Thursday, December 06, 2018 9:02:31 PM
IPIX is scheduled to have an End of Phase 2 meeting with the FDA for its Brilacidin-Oral Mucositis. The results could (the operative word being could) propel IPIX into a partnership that would include significant upfront payments that would end its current financial shortcomings and should prevent dilution for shareholders down the line.
There is NO guarantee that a deal will be forthcoming immediately after a successful EOP mtg. That certainty is being purported by those trying to make it appear as though IPIX has missed a deadline, one the company never made, so that they can then say such failure shows the company is doomed. But a successful mtg will show IPIX is the leader for an easy delivery treatment that should bring about a cure, or preventative measure, for this devastating condition which affects tens to hundreds of thousands of patients.
Though there is no guarantee a partnership will follow immediately, there is a CHANCE that a BP could sign a partnership prior to the mtg so that they can sit in on the meeting or there is already a deal pending a successful EOP meeting. Nobody knows, nobody can make statements of fact as to timing. Many expect the chance for a partnership to be very strong, others not so. My opinion is to look at the trial data and that shows an overwhelming positive result of the P2b trial so I have no worries the meeting will end successfully.
If the EOP meeting is successful, IPIX should see a partnership in the near future - whatever that means. Is that days, weeks, or maybe a month or more? Nobody knows, many expect pretty darn soon, others not so, but everybody knows if the meeting is successful IPIX is on its way to major success. The BTD issue is secondary to a successful EOP meeting though some talk as though it is another precursor to the life of the company.
One has to realize in IPIX that due to the nature of the business timing is not something one can pin down to a certainty so one must be able to handle the risk and the stress of waiting.
But the wait should well prove worthwhile. I am very excited for what the rest of the year brings to IPIX and have no worries that our science will shine as it has through all the clinical trials to date.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM